Last reviewed · How we verify
Minoxidil Topical
Minoxidil Topical is a Potassium channel opener Small molecule drug developed by Dr. dr. Lili Legiawati, SpKK(K). It is currently FDA-approved for Androgenetic alopecia (male and female pattern hair loss).
Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle.
Minoxidil Topical is used to treat conditions such as Androgenetic Alopecia, Female Pattern Hair Loss, and Alopecia Areata, as well as Vitiligo - Macular Depigmentation. It works by opening the Sulfonylurea receptor 2, Kir6.2, which is a mechanism classified as a small molecule opener.
At a glance
| Generic name | Minoxidil Topical |
|---|---|
| Sponsor | Dr. dr. Lili Legiawati, SpKK(K) |
| Drug class | Potassium channel opener |
| Target | ATP-sensitive potassium channels |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Minoxidil topical works by dilating blood vessels in the scalp, improving nutrient and oxygen delivery to hair follicles. It also directly stimulates hair follicle growth and extends the duration of the active growth phase, thereby increasing hair density and slowing hair loss. The exact molecular mechanism remains incompletely understood but involves potassium channel activation and potentially growth factor signaling.
Approved indications
- Androgenetic alopecia (male and female pattern hair loss)
Common side effects
- Scalp irritation
- Dryness
- Itching
- Unwanted facial hair growth
- Contact dermatitis
Key clinical trials
- Androgenic Alopecia TH07 Clinical Trial (PHASE3)
- Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer (EARLY_PHASE1)
- Topical Methotrexate vs Minoxidil for Localized Alopecia Areata (PHASE4)
- Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (PHASE2)
- Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia (NA)
- Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia (PHASE2)
- Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia (PHASE3)
- Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minoxidil Topical CI brief — competitive landscape report
- Minoxidil Topical updates RSS · CI watch RSS
- Dr. dr. Lili Legiawati, SpKK(K) portfolio CI
Frequently asked questions about Minoxidil Topical
What is Minoxidil Topical?
How does Minoxidil Topical work?
What is Minoxidil Topical used for?
Who makes Minoxidil Topical?
What drug class is Minoxidil Topical in?
What development phase is Minoxidil Topical in?
What are the side effects of Minoxidil Topical?
What does Minoxidil Topical target?
Related
- Drug class: All Potassium channel opener drugs
- Target: All drugs targeting ATP-sensitive potassium channels
- Manufacturer: Dr. dr. Lili Legiawati, SpKK(K) — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Androgenetic alopecia (male and female pattern hair loss)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing